Emory and NIH continue public-private partnership advancing Alzheimer’s research
The National Institutes of Health is launching the next version of AMP AD (Accelerating Medicines Partnership Alzheimer’s Disease), a public-private partnership that takes an open science, big data approach to identifying biological targets for therapeutic intervention.
The National Institute on Aging will lead research efforts for AMP AD 2.0 and has pledged to contribute $61.4 million over five years. This includes funding six multi-institutional, cross-disciplinary academic research teams, including the team at Goizueta Alzheimer’s Research Center at Emory University, along with a data coordinating center at Sage Bionetworks.
Emory researchers served as a founding academic team for the first iteration of the AMP AD when the initiative began in 2014. Led by Allan Levey and Nicholas T. Seyfried, Emory investigators will play an integral role in AMP AD 2.0 as it seeks to support new technologies,
Groundbreaking New Study in Lancet Rheumatology Shows Potential Strategy for Safer Steroid Use in Lupus
Dr. Eric Morand Publishes Results Funded by LRA s Distinguished Innovator Award
News provided by
Share this article
Share this article
NEW YORK, April 1, 2021 /PRNewswire/ Results of critical work funded by the Lupus Research Alliance Distinguished Innovator Award to Dr. Eric Morand suggests a path toward making lupus treatment with steroids effective at lower doses, lessening harmful side effects.
In a study just published in
Lancet Rheumatology, Dr. Morand (with first author rheumatology fellow. Dr. Melissa Northcott) reports identifying a group of biological markers that can indicate how much steroid lupus patients have been exposed to, since the amount that is active in the body is more important than the amount taken. The paper further shows that high activity of proteins made by the immune system, called interferons, can block the effects of steroid treatmen